Is pericardial effusion a negative prognostic marker? Meta-analysis of outcomes of pericardial effusion.


Journal

Journal of cardiovascular medicine (Hagerstown, Md.)
ISSN: 1558-2035
Titre abrégé: J Cardiovasc Med (Hagerstown)
Pays: United States
ID NLM: 101259752

Informations de publication

Date de publication:
Jan 2019
Historique:
pubmed: 28 11 2018
medline: 29 5 2019
entrez: 28 11 2018
Statut: ppublish

Résumé

The prognostic relevance and the prevalence of pericardial effusion in several diseases are not well established. The aim of this meta-analysis is to summarize the available evidence related to pericardial effusion prevalence and outcomes according to the cause. Articles investigating the prognosis of pericardial effusion were identified by literature search. Twenty-three studies were finally included (17 022 patients). All-cause mortality was the primary end-point. Secondary end-point was the prevalence of pericardial effusion in most common diseases related to this clinical condition. The pooled prevalence of pericardial effusion was 19.5% [95% confidence interval (CI): 14.3-26]. After a mean follow-up of 36 ± 23 months, the risk of death was higher in pericardial effusion patients [hazard ratio (HR) 1.59, 95% CI 1.37-1.85, P < 0.0001]. Stratifying for the main disease, pericardial effusion is associated with unfavourable outcome in all available subgroups: pulmonary arterial hypertension HR 1.53 (95% CI: 1.22-1.92; P < 0.0001), chronic heart failure (CHF) HR 1.53 (95% CI: 1.22-1.92; P < 0.0001), myocardial infarction HR 2.65 (95% CI: 1.4-4.99; P = 0.003) and malignancies HR 1.75 (95% CI: 1.09-2.81, P = 0.021). The lack of data concerning the idiopathic pericardial effusion does not permit a secure risk assessment but the average incidence of mortality is 14.5% (95% CI: 7.7-25.6). Pericardial effusion should be considered a marker of the severity of the underlying disease, whereas for idiopathic pericardial effusion the correlation with poor prognosis is less clear.

Sections du résumé

BACKGROUND BACKGROUND
The prognostic relevance and the prevalence of pericardial effusion in several diseases are not well established. The aim of this meta-analysis is to summarize the available evidence related to pericardial effusion prevalence and outcomes according to the cause.
METHODS METHODS
Articles investigating the prognosis of pericardial effusion were identified by literature search. Twenty-three studies were finally included (17 022 patients). All-cause mortality was the primary end-point. Secondary end-point was the prevalence of pericardial effusion in most common diseases related to this clinical condition.
RESULTS RESULTS
The pooled prevalence of pericardial effusion was 19.5% [95% confidence interval (CI): 14.3-26]. After a mean follow-up of 36 ± 23 months, the risk of death was higher in pericardial effusion patients [hazard ratio (HR) 1.59, 95% CI 1.37-1.85, P < 0.0001]. Stratifying for the main disease, pericardial effusion is associated with unfavourable outcome in all available subgroups: pulmonary arterial hypertension HR 1.53 (95% CI: 1.22-1.92; P < 0.0001), chronic heart failure (CHF) HR 1.53 (95% CI: 1.22-1.92; P < 0.0001), myocardial infarction HR 2.65 (95% CI: 1.4-4.99; P = 0.003) and malignancies HR 1.75 (95% CI: 1.09-2.81, P = 0.021). The lack of data concerning the idiopathic pericardial effusion does not permit a secure risk assessment but the average incidence of mortality is 14.5% (95% CI: 7.7-25.6).
CONCLUSION CONCLUSIONS
Pericardial effusion should be considered a marker of the severity of the underlying disease, whereas for idiopathic pericardial effusion the correlation with poor prognosis is less clear.

Identifiants

pubmed: 30480582
doi: 10.2459/JCM.0000000000000720
doi:

Types de publication

Journal Article Meta-Analysis Systematic Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

39-45

Auteurs

Ovidio De Filippo (O)

Cardiovascular and Thoracic Department and Department of Medical Sciences, University Cardiology, AOU Città della Salute e della Scienza di Torino, Torino, Italy.

Paolo Gatti (P)

Cardiovascular and Thoracic Department and Department of Medical Sciences, University Cardiology, AOU Città della Salute e della Scienza di Torino, Torino, Italy.

Sara Rettegno (S)

Cardiovascular and Thoracic Department and Department of Medical Sciences, University Cardiology, AOU Città della Salute e della Scienza di Torino, Torino, Italy.

Mario Iannaccone (M)

Cardiovascular and Thoracic Department and Department of Medical Sciences, University Cardiology, AOU Città della Salute e della Scienza di Torino, Torino, Italy.

Fabrizio D'Ascenzo (F)

Cardiovascular and Thoracic Department and Department of Medical Sciences, University Cardiology, AOU Città della Salute e della Scienza di Torino, Torino, Italy.

George Lazaros (G)

1st Department of Cardiology, University of Athens Medical School, Hippokration General Hospital, Athens, Greece.

Antonio Brucato (A)

Dipartimento di Scienze Biomediche e Cliniche 'L. Sacco', University of Milano.

Dimitrios Tousoulis (D)

1st Department of Cardiology, University of Athens Medical School, Hippokration General Hospital, Athens, Greece.

Yehuda Adler (Y)

The Sackler Faculty of Medicine, Tel Aviv University, Israel.

Massimo Imazio (M)

Cardiovascular and Thoracic Department and Department of Medical Sciences, University Cardiology, AOU Città della Salute e della Scienza di Torino, Torino, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH